Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target and the rates of infection were higher with secuk inumab than with placebo in both studies and were similar to those with etanercept.
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians, including PIER (Physicians’ Information and Education Resource) and MKSAP (Medical Knowledge and SelfAssessment Program).
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
- M. Lebwohl, B. Strober, A. Nirula
- Medicine, BiologyThe New England journal of medicine
- 30 September 2015
Bdalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis, and was found to be superior to placebo at week 12 with respect to a 100% reduction in PASI score (PASI 100).
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.
- G. Krueger, J. Koo, M. Lebwohl, A. Menter, R. Stern, T. Rolstad
- MedicineArchives of dermatology
- 1 March 2001
The unprecedented response to the survey provides compelling evidence that individuals with psoriasis believe that the disease has a profound emotional and social as well as physical impact on their quality of life.
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and…
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
Ingenol mebutate gel for actinic keratosis.
- M. Lebwohl, N. Swanson, Lawrence Anderson, A. Melgaard, Zhenyi Xu, B. Berman
- MedicineThe New England journal of medicine
- 14 March 2012
Ingenol mebutate gel applied topically for 2 to 3 days is effective for field treatment of actinic keratoses, and adverse events were generally mild to moderate in intensity and resolved without sequelae.